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Management of axilla is an integral part of treatment of carcinoma breast. Axillary  lymph 
node dissection has a well-established role in regional disease control and it provides 
information about the histopathological status which has significant prognostic and 
therapeutic implications. However  only around 30 percent  of the of clinically node negative  
patients prove to be histopathologically  node positive which means  that 70 percent of 
clinically node negative patients undergo axillary dissection and  are exposed to  its   
morbidities  like neuropathies, seromas and upper extremity lymphedema. This can be 
avoided with a sentinel lymph node (SLN) biopsy. This study aimed to assess the feasibility 
of localization of  the sentinel node with the  blue dye alone and compare the nodal  tumor 
positivity in relation to blue dye positivity . Thirty  five  patients with  breast  cancers with 
stages T1-T3, N0, and one patient with T3 N1 M0 disease  who had become node negative 
post chemo therapy were included in the study.5 patients  with    breast cancer clinically node 
negative axilla    were excluded from the study after they have found to have axillary nodes 
after ultrasound examination. Totally 36 patients were evaluated.  This study demonstrates 
that sentinel node  localization is possible with  methylene  blue dye alone with 88.88% 
localisation rate. Though limited by small sample size this study has shown a low false 
negative rate of 6.25%. which denotes  that SLN biopsy using methylene  blue dye alone  is a 
highly  reliable and predictable technique to stage the axilla in breast cancer patients. This 
technique may help to avoid   complete axillary lymph node dissection in sentinel node 





Management of axilla is an integral part of treatment of carcinoma breast. 
Axillary  lymph node dissection has a well-established role in regional disease 
control and it provides information about the histopathological status which has 
significant prognostic and therapeutic implications(1).However  only around 30 
percent  of the of clinically node negative  patients prove to be histopathologically  
node positive which means  that 70 percent of clinically node negative patients 
undergo axillary dissection and  are exposed to  its   morbidities  like neuropathies, 
seromas and upper extremity lymphedema. This can be avoided with a sentinel 
lymph node (SLN) biopsy. Published data till date use vital blue dye and /or 
99mTechnetium labelled colloid with gamma probe for the identification of sentinel 
lymph nodes. A combination of the two techniques has been found to be the best 
and   is recommended for optimal outcome. Blue dye guided SLN identification 
may be the only available option in countries with low resources due to prohibitive 
price of gamma probes. This study was done to analyse methylene blue dye uptake 
after peri-tumoural injection and compare tumour positivity in nodes stained and 







REVIEW OF LITERATURE 
Addressing the axillary nodes is an integral component in the loco regional 
management of early breast cancer. A formal axillary lymph node dissection was 
until recently the standard procedure of choice for the management in the majority 
of the patients irrespective of primary tumour characteristics. Around 25-30% of 
patients have nodal disease at the time of diagnosis. For these patients removal of 
lymph nodes minimises the chance of loco regional relapse and can provide crucial 
information for guiding systemic adjuvant treatments. Moreover, axillary lymph 
node status remains the single most important prognostic factor in breast cancer (2). 
Nonetheless, for node negative patients axillary lymph node dissection represents 
over treatment and can be associated with significant morbidity. Sentinel node 
biopsy (SNB) permits accurate axillary staging of patients with early breast cancer 
with clinically node negative axilla. Sentinel node biopsy has less morbidity and 
fewer complications than axillary lymph node dissection (3). 
Anatomy of the breast(4) 
The adult female breast is located within the superficial fascia of the anterior 
chest wall. The base of the breast extends from the second rib above to the fifth or 
sixth rib below, and from the sternal border medially to the mid-axillary line 
laterally. Two-thirds of the base of the breast lies anterior to the pectoralis major 
muscle, the remainder lies over the serratus anterior muscle. A small part may lie 
over the aponeurosis of the external oblique muscle. 
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In about 95 percent of women there is a prolongation of the upper lateral 
quadrant toward the axilla. This tail (of Spence) of breast tissue enters a hiatus (of 
Langer) in the deep fascia of the medial axillary wall. This is the only breast tissue 
found normally beneath the deep fascia.  
Skin 
The epidermis of the areola and the nipple is distinguished from that of the 
surrounding skin by the colour imparted by blood vessels carried close to the 
surface in long dermal papillae. In females at puberty, and with each pregnancy, 
there is an increase in the melanin content of the basal cells, further darkening the 
area. The dermis of the skin merges with the superficial fascia, which envelops the 
parenchyma of the breast. 
Superficial Fascia 
The superficial fascia  enveloping the breast is continuous with the 
superficial abdominal fascia (of Camper) below, and the superficial cervical fascia 
above. Anteriorly, it merges with the dermis of the skin. 
Deep Fascia 
 The deep pectoral fascia envelops the pectoralis major muscle and is 
continuous with the deep abdominal fascia below. It attaches to the sternum 
medially and to the clavicle and axillary fascia above and laterally. Along the 
lateral border of the pectoralis major muscle, the anterior lamina of the deep 
pectoral fascia unites with the fascia of the pectoralis minor muscle and, more 
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inferiorly, with the fascia of the serratus anterior. A posterior extension of this 
fascia is continuous with the fascia of the latissimus dorsi and forms the so-called 
suspensory ligament of the axilla. 
     Anatomy of the axilla 
The axilla is defined as a pyramidal space having an apex, a base, and four 
walls. The apex is a triangular space bordered by the clavicle, the upper border of 
the scapula, and the first rib, which is sometimes called the cervico-axillary canal. 
The base consists of the axillary fascia beneath the skin of the axillary fossa. The 
anterior wall is composed of three muscles (the pectoralis major, the pectoralis 
minor, and the subclavius) and the clavipectoral fascia, which envelops the muscles 
and fills the spaces between them. The posterior wall is formed by the scapula and 
three muscles: the Subscapularis, the Latissimus dorsi, and the Teres major. The 
medial wall consists of the lateral chest wall, with the second to sixth ribs, and the 
serratus anterior muscle. The lateral wall is the narrowest of the walls, being 
formed by the bicipital groove of the humerus.The axilla contains lymph nodes, the 
axillary sheath, which covers blood vessels and nerves, and the tendons of the long 







FIGURE-1 Lateral wall of the axilla 
 
Morphology of breast 
 
Each breast is composed of between 15 and 20 lobes, some larger than 
others, within the superficial fascia, which is loosely connected with the deep 
fascia. Between the superficial and deep fascia is the retromammary 
(submammary) space, which is rich in lymphatics.Each lobe has a duct terminating 
at the nipple. These lobes, together with their ducts, are anatomical but not surgical 
units. In the fat-free area under the areola, the dilated portions of the lactiferous 
ducts (the lactiferous sinuses) are the only sites of actual milk storage. Intraductal 
papillomas may develop here. The suspensory ligaments of Cooper form a network 
of strong connective tissue fibres passing between the lobes of parenchyma and 
connecting the dermis of the skin with the deep layer of the superficial fascia. 
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Occasionally the superficial fascia is fixed to the skin in such a way that ideal 
subcutaneous total mastectomy is impossible. With malignant invasion, portions of 
the ligaments of Cooper may contract, producing a characteristic fixation and 
retraction or dimpling of the skin. This must not be confused with the retraction of 
‘peau d’orange’ secondary to lymphatic obstruction. 
 
Vascular  system  of the breast 
1. Thoracic Artery 
The internal thoracic (or internal mammary) artery is a branch of the 
subclavian artery that parallels the lateral border of the sternum behind the internal 
intercostal muscles. 
2. Branches of the Axillary Artery 
Four branches of the axillary artery may supply the breast. They are, in order 
of appearance: (1) the supreme thoracic branch, (2) the pectoral branches of the 
thoracoacromial artery, (3) the lateral thoracic arteries, and (4) unnamed mammary 
branches. 
3. Intercostal Arteries 





Anatomy of the lymphatics(5) 
The lymphatic system consists of a fluid (lymph), vessels that transport the 
lymph and organs that contain lymphoid tissue 
Lymph is a fluid similar in composition to blood plasma. It is derived from 
blood plasma as fluids pass through capillary walls at the arterial end. As the 
interstitial fluid begins to accumulate, it is picked up and removed by tiny 
lymphatic vessels and returned to the blood. As soon as the interstitial fluid enters 
the lymph capillaries, it is called lymph. Returning the fluid to the blood prevents 
edema and helps to maintain normal blood volume and pressure. 
Lymphatic vessels carry fluid away from the tissues. The smallest lymphatic 
vessels are the lymph capillaries, which begin in the tissue spaces as blind-ended 
sacs. Lymph capillaries are found in all regions of the body except the bone 
marrow, central nervous system, and tissues that lack blood vessels (epidermis). 
The wall of the lymph capillary is composed of endothelium in which the simple 
squamous cells overlap to form a simple one-way valve. This arrangement permits 
fluid to enter the capillary but prevents lymph from leaving the vessel. The 
microscopic lymph capillaries merge to form lymphatic vessels. Small lymphatic 
vessels join to form larger tributaries, called lymphatic trunks, which drain large 
regions. Lymphatic trunks merge until the lymph enters the two lymphatic ducts 
namely the right lymphatic duct and the thoracic duct. The right lymphatic duct 
drains lymph from the upper right quadrant of the body. The thoracic duct drains all 
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the rest. Like veins, the lymphatic tributaries have thin walls and have valves to 
prevent backflow of blood. There is no pump in the lymphatic system like the heart 
in the cardiovascular system. The pressure gradients to move lymph through the 
vessels come from the skeletal muscle action, respiratory movement, and 
contraction of smooth muscle in vessel walls. 
The lymphatic organs include lymph nodes, tonsil, spleen and thymus. 
Lymphatic organs are characterized by clusters of lymphocytes and other cells, 
such as macrophages, enmeshed in a framework of short, branching connective 
tissue fibres. Lymph nodes are small bean-shaped structures that are usually less 
than 2.5 cm in length. They are widely distributed throughout the body along the 
lymphatic pathways where they filter the lymph before it is returned to the blood. 
Lymph nodes are not present in the central nervous system. There are three 
superficial regions on each side of the body where lymph nodes tend to cluster. 
These areas are the inguinal nodes in the groin, the axillary nodes in the armpit, and 








FIGURE-2  Lymph node structure 
  
 
A typical lymph node is surrounded by a connective tissue capsule and is 
divided into compartments called lymph nodules. The lymph nodules are dense 
masses of lymphocytes and macrophages, separated by spaces called lymph 
sinuses. The afferent lymphatics enter the node at different parts of its periphery, 
which carry lymph into the node; entering the node on the convex side. The lymph 
moves through the lymph sinuses and enters an efferent lymphatic vessel, located at 






Anatomy of the axillary lymph nodes 
The lymphatic vessels of the upper limb, most of those from the breast, and 
cutaneous lymph vessels of the trunk above the level of umbilicus drain to the 
axillary lymph nodes. The primary route of lymphatic drainage of the breast is 
through the axillary lymph nodes. Unfortunately the boundaries for this group of 
lymph nodes found in the axilla are not well demarcated. Thus there has been 
considerable variation in the names given to lymph node groups. 
Anatomical  classification of axillary lymph node groups 
1. LATERAL - Above the axillary vein, drain the upper limb 
2. ANTERIOR - Along the inferior border of the pectoralis minor drain most 
of the breast  
3. POSTERIOR - Subscapular nodes, drain the shoulder 
4. CENTRAL - Near the base of the axilla receive lymph from the preceding 
three groups and form the most common palpable group. 
5. APICAL – Lies medial to the axillary vein and superior to the pectoralis 
minor. Receive lymph from all the other groups sometimes directly from the breast. 
They drain into two or three subclavian trunks which enter the jugular-subclavian 
venous confluence or join a common lymphatic duct or empty into lower deep 




Surgical classification of axillary lymph node groups 
1. Axillary vein group 
2. External mammary group, 
3. Scapular group, 
4. Central group, 
5. Subclavicular group,  
6. Inter pectoral or Rotter s group 
 
Surgeons also define the axillary lymph nodes with respect to their 
relationship with the pectoralis minor muscle. 
Level I - Lymph nodes located lateral or below the lower border of the 
pectoralis minor muscle and include external mammary, scapular and axillary vein 
nodal groups 
Level II- Lymph nodes deep or posterior to the pectoralis minor and include 
central and some of the subclavicular lymph node group 
Level III - Lymph nodes medial or superior to the upper border of the 




Lymphatic system of the breast 
The lymphatics of the breast form an extensive and complex network of 
periductal and perilobular vessels which drain principally to the axillary nodes. The 
lymphatic vessels occur in three interconnecting groups (6) 
1. Primary set of channels within the gland  
2. Sub areolar plexus 
3. A plexus on the deep surface of the breast 
Although the internal mammary nodes were recognized by Handley as a 
primary route for lymphatic drainage from medial and central zones of the 
breast(7), the majority of the breast cancer metastasise to the axillary nodes 
irrespective of the index quadrant(8). Fewer than 10% of the node positive tumours 
exclusively affect the internal mammary nodes (9). Accessory pathways of 
lymphatic drainage routes assume importance in more advanced states of disease 
when the axillary drainage routes become obstructed (10) and include the following 
routes, 
1. Sub sternal crossover (contralateral internal mammary chain)(11) 
2. Presternal cross over (contralateral breast) 
3. Mediastinal (12) 
4. Rectus abdominus sheath to sub diaphragmatic and sub peritoneal plexus. 
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Axillary lymph node dissection (ALND) 
ALND refers to removal of lymph nodes in the axilla. A complete ALND 
refers to extirpation of the lymph nodes from all the three levels. A partial ALND 
refers to removal of lymph nodes from level I and level II, and Axillary sampling 
indicates only resection of level I nodes.  
 The axilla is a pyramidal space with an apex directed into the root  of the 
neck; base bounded in front by the anterior axillary fold, which consists of the two 
pectoral muscles, the subclavius muscle and behind by the posterior axillary fold, 
formed by Teres major and Latissmus dorsi muscle and medially by the chest wall. 
The axillary tissue is composed of adipose tissue and lymph nodes. 
 
Steps of axillary dissection 
1. Definition of pectoralis muscles 
 The lateral edge of the pectoralis major muscle is retracted medially 
to expose the pectoralis minor muscle and allow interpectoral dissection of Rotter’s 
lymph nodes.  
2. Identification of Latissmus dorsi 
 The anterior surface of the Latissmus dorsi muscle is the lateral 
border of axillary dissection. 
3. Clavipectoral fascia 
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 The clavipectoral fascia is divided at the level of inferior axillary 
sheath to expose the underlying fat pad and axillary lymph nodes within the fat.  
4. Axillary vein  
Dissection is carried posteriorly until the axillary vein is exposed.( 13) 
5. Mobilization of axillary fat pad 
 The fatty tissue and lymph nodes cleared off the chest wall and the 
inferior surface the axillary vein. 
6. Identification of nerves 
 The position of thoraco dorsal nerve and long thoracic nerve can vary 
from patient to patient. The best approach is to preserve all neuro vascular 
structures until full axillary anatomy can be determined. The thoraco dorsal neuro 
vascular pedicle can be identified by dissecting in the mid axilla. The long thoracic 
nerve can be identified by blunt dissection just below the medial aspect of the 
axillary vein and lateral to the chest wall. 
Extent of dissection  
 In general level I and level II anatomic ALND is the preferred procedure for 
axillary assessment (14). Typical level I/II dissection should yield more than 10 
axillary nodes.(15-16)  
 
Routine removal of level III nodes is unnecessary and should be carried out to 
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maximize local control only if grossly positive lymph nodes are identified intra 
operatively at level I and level II. Level III lymph node dissection increases the 
morbidity of ALND (17). 
Completion of ALND -Once the thoraco dorsal and long thoracic nerves are 
identified, contents of the axilla can be removed from the defined boundaries. 
Methods of axillary node sampling 
The recognition that axillary dissection was principally a staging procedure 
with concomitant morbidity led to investigation of alternative procedures for 
staging the axilla these included 1. Four node axillary sampling, 2.sentinel node 
biopsy 
Four node axillary sampling 
 Axillary sampling was introduced  more than two decades ago  by Sir 
Patrick Forrest (18) the original technique of blind four node sampling of axilla 
could stage with estimated accuracy of 97%(19). This blind four node sampling is 
not associated with impaired loco regional control or any detriment in overall 
survival. (20)  For patients found to be node positive on sampling, the axilla can be 
irradiated or surgically cleared (21) 
Sentinel node biopsy 
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The sentinel node hypothesis presupposes an orderly spread of cancer cell  
to the sentinel node then to the higher echelon nodes. If the sentinel node is 
free from metastases, the non-sentinel nodes are presumed to be tumour free.  
History of sentinel node concept 
 The concept of sentinel node biopsy is based on two basic principles: the 
existence of an orderly and predictable pattern of lymphatic drainage to a regional 
lymph node basin, and the functioning of a first echelon lymph node as an effective 
filter for tumour cells. With the wide spread use of sentinel node biopsy, sufficient 
data was needed to prove that sequential lymphatic dissemination and entrapment 
of tumour cells in first draining lymph nodes does occur. 
The concept of selecting a single lymph node to represent a nodal basin is 
very old.  In 1951 Gould sent a normal appearing node at the junction of anterior 
and posterior facial vein for frozen. Intraoperative examination of this lymph node 
in its typical anatomical location guided the decision to perform a radical neck 
dissection during the following parotidectomies (22). 
Two decades later, Cabañas observed the existence of sentinel lymph node 
in carcinoma penis around the superficial epigastric vein in 1977 (23). These nodes 
were identified with lymphangiography. Kett et al administered contrast medium in 
breast lymphatics that were visualised with the aid of areolar blue dye injection 
(24). They observed flow to an isolated lymph node, called the ‘Sorgius’ node, and 
subsequent drainage through many lymphatic vessels and lymph nodes to the 
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collecting system around the axillary vein. Using breast lymphoscintigraphy in 
1980, Christensen et al observed primary draining nodes [25]. Haagensen studied 
the route of metastases through the axillary lymph node and stated that the nodes of 
the central group are most often exclusively involved [26]. He used the term 
sentinel node for specific lymph nodes of the inferior deep cervical group. 
             
  Morton et al have used cutaneous lymphoscintigraphy with colloidal gold 
since 1977 to identify the lymphatic drainage pattern of melanomas located at 
ambiguous sites [27]. In addition to this preoperative procedure, they also 
developed a technique for intraoperative mapping to selectively remove lymph 
nodes on the direct drainage pathway from the primary melanoma. This sentinel 
node was considered to be the first site of metastatic disease. The work of the group 
at the John Wayne Cancer Institute initiated one of the most interesting recent 
developments in surgical oncology (28). Giuliano applied the concept of a negative 
lymph node to eliminate the need for radical dissection (29). 
Indications and contraindications of axillary sentinel node biopsy in breast cancer 
 Clinical Indications of sentinel node biopsy have been changing and still 
there is debate on some of   them. Sentinel node biopsy is indicated in most of the 
women with clinically node negative axilla with invasive or micro invasive breast 






{DCIS - ductal carcinoma in situ; Controversial - indications suggest that the 
it is not universally accepted or the evidence behind the practice is limited.} 
Contraindications 
1.Prior axillary surgery  
2.DCIS when  lumpectomy  is planned 
Clinical scenario Indication of sentinel node biopsy 
T1 or T2 tumours Established 
Older age Established 
Obesity Established 
Before preoperative systemic 
 
Established 
Male breast cancer Established 
DCIS with mastectomy Established 
Internal mammary chain Established but controversial 
DCIS without mastectomy Controversial 
Pregnancy Controversial 
Suspicious, palpable axillary 
 
Controversial 
T3 or T4 tumours Controversial 
Multicentric or multifocal 
 
Controversial 
Prior diagnostic or excisional 
  
Controversial 
Prior axillary surgery Controversial 
Prior non-oncologic breast 
 
Controversial 
After preoperative systemic 
 
Controversial 
Inflammatory breast cancer Not recommended 
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3.Prior breast surgery 
4. Pregnancy 
5. Inflammatory breast cancer. 
 
Role of ultrasound in sentinel node evaluation  
 For women with clinically suspicious axillary nodes, axillary ultrasound 
with fine needle aspiration or core needle biopsy provides a mean to identify the 
patients who have positive nodes and thus need ALND rather than the SLND.The 
efficacy of this approach is variable between centres because the accuracy of 
ultrasound examination is operator dependent (32) 
Lymphatic mapping techniques for sentinel node biopsy  
Given the rapid growth of lymphatic mapping and sentinel node biopsy 
surgical groups have developed several variations and many technical aspects are 
evolving which include 
Choice of mapping label 
Radio isotope quantity and processing 
Injection site 
Timing of injection 




Choice of mapping label  
Radio isotope 
Blue dye 
Both radio isotope and blue dye 
Radio isotope 
 Krag and colleagues first described the use of radioisotope alone for breast 
cancer in 1993, using technetium-99m sulphur colloid and a hand held gamma 
probe(33). The sentinel node identification rate was 98% with a false negative rate 
of 11%. Technetium-99 m sulphur colloid is the most commonly used isotope for 
lymphatic mapping in United States. In Europe technetium-99 m colloidal albumin 
is used.   The dose range from -0.1 to 4 mCi 
Blue dye 
 Isosulfan blue dye (Lymphazurin 1%) was studied extensively in 
melanoma. The use of Isosulfan blue dye as a single agent in sentinel node biopsy 
for carcinoma breast was reported by Giuliano and colleagues(34). The 
disadvantage is the risk of life threatening allergic and anaphylactic reactions. The 
reported allergic reactions rate ranges from 1% to 3%. They include utricaria,rash, 
pruritus, hypotension and anaphylaxis. Overall isosulfan blue dye has excellent 




Methylene blue dye has also been successful in lymphatic mapping for 
breast cancer. Simmons et al used methylene blue in the identification of lymphatic 
mapping in breast cancer (35). Methylene blue was compared with Isosulfan blue 
by Blessing et al in 2002 and found similar identification rates (36).Methylene blue 
is preferred by some authors because of its lower cost and less complications. 
Methylene blue must be injected subcutaneously. Inadvertent injection into the 
dermis has resulted in severe skin reactions including necrosis and dermolysis. 
 
Combination of blue dye and radioisotope  
The combination of blue dye and radioisotope improves the sentinel node 
identification rate. Albertini et al first reported the successful use of lymphatic 
mapping with blue dye and radioisotopes prospectively (37).The results confirmed 
that the combination improves the sentinel node identification rate and dual agent 
lymphatic mapping has been accepted universally (38). Some centres have selected 
to rely on radioisotope mapping alone, given the potentially life-threatening allergic 
reactions of isosulfan blue dye. 
 
Injection site for mapping agents 
1. Peritumoural injection. 




Peritumoural injection replicates the intramammary lymphatic pathway that 
has been traversed by metastases. The initial data regarding sentinel node biopsy 
used peritumoural injection. For patients who have nonpalpable tumours this 
method has proven to be difficult and time consuming as it requires the use of 
additional imaging modalities to guide the Peri-tumoural injection of radioisotopes. 
Peri-tumoural injections also have a  higher potential for shine through where 
residual radioactivity from the peri-tumoural injection site creates misleading 
background activity detected by the gamma probe in the axilla. It is for these 
reasons that alternate injection sites have been tried. 
Subareolar and dermal injection  
Nearly all breast tissue lymphatics pass through the sub areolar plexus of 
Sappey and then to the axillary basin. Non palpable and multicentric tumours can 
be studied with sub areolar and dermal injection and they do not have the shine 
through effect. Sub areolar and dermal injection of blue dye may cause 
considerable skin discoloration which may last for months. In addition up to 10% 
of breast cancers may demonstrate non axillary lymphatic drainage with sentinel 
nodes found in the internal mammary or supraclavicular nodal basins; so, not all 
breast tumours will have the same drainage patterns as the overlying skin and 





Patients undergoing lymphatic mapping with radioisotopes most often  
receive  a   
pre-operative lymphoscintigram,to aid in sentinel lymph node (SLN) 
identification. 
 Pre-operative lymphoscintigram, consists of anterior and lateral view and 
specific patient positioning to optimize transit time and drainage (40). Scanning is 
done after 20 minutes and images are repeated till identification of SLN basin then 
the patient is taken to the operating room for SLNB..McMasters and colleagues 
(41) evaluated the role of pre-operative lymphoscintigram, in breast cancer. In the 
study, a pre-operative lymphoscintigram, was performed in 348 of 588 patients, and 
240 patients did not receive scans. The SLN was identified in 221 of the 240 
patients who did not undergo preoperative scanning. In these patients, the false-
negative rate was 1.6%.  The authors found no significant difference in the SLN 
identification rate, false-negative rate, or number of SLNs removed  between 
patients receiving PL and those proceeding to operation without scanning. 
         Borgstein and colleagues(42) also studied the role of PL in breast 
cancer patients. The authors found that the intraoperative gamma probe was more 
sensitive in detecting radioactive nodes in the axilla than the PL, even when 
delayed images were obtained. Data have continued to emerge questioning the 
ability of preoperative lymphoscintigraphy to improve the accuracy of SLNB and 
24 
 
some centres have abandoned the technique, relying on the intra operative gamma 
probe to detect radioactive SLNs. 
 Timing of radio isotope injection 
Lymphatic mapping with radio isotopes is performed either as a 1 or 2 day 
procedure.(43)  The single day procedure requires isotope injection on the morning 
of surgery  followed by serial imaging  1 to several hours after injection until the  
SLN is identified. The effect of delay on patients and on operating room has led to 
use a 2 day mapping procedure, with injection of radio isotopes 1 day before 
operation.  Based on the current literature, 2 day lymphatic mapping procedure is 
safe and reliable method of SLN identification.(44) 
Technique 
 Blue dye  
The patient is prepped and draped in the operating room. The surgeon injects 
3-5ml of blue dye peritumourally or sub dermally 
 The axillary fascia is entered through an inferior axillary incision. Careful 
search is made for lymphatic channels leading to blue stained node. All blue nodes 
and nodes at the end of the blue lymphatic channel are removed .Care must be  
taken to identify the most blue node and the blue node most proximal to the tumour 
in the axilla , because the dye transit time is  rapid  and blue staining of distal,  non-
sentinel axillary LNs is not uncommon. Failure to consider the node at the end of 
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blue lymphatic channel as a sentinel node whether or not the node itself appears 
blue is the most common technical error (45). 
  
 
Radioactive colloid (46) 
Technetium-99m-labeled colloids with a particle size of 20 –100 nm and an 
injection volume of 0.2–1.0 mL generally are used.  The amount of radioactivity 
has to be determined according to the time between radio-colloid injection and the 
surgical procedure to obtain a sufficient radio-colloid uptake in the lymph node and 
a high target signal intensity. 
 
If surgery is planned 24 hours after the injection and a probe with a 
sensitivity of 10 cps/kBq is used, then activity of 150 –250 megabecquerel (MBq) 
will be needed. With a nuclide half-life of 6 hours (Technetium-99) and an 
injection time 6 hours prior to SLNB, the amount of radioactivity required is 
reduced by 50%. In 1-day protocols, 10 –50 MBq are sufficient. Tracers may be 
injected into the peritumoural tissue, intratumourally, intradermally or in the 
subareolar region. The patient lies supine for imaging on the gamma-camera bed 
3hours after the injection of tracer .Anterior and 45° anterior oblique static 
scintigraphic images are obtained by using a dual head gamma camera with low 
energy high resolution collimator. The site of any suspected sentinel node can be 
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localised on overlying skin on the 45° anterior oblique image and the skin of the 
patient on the identical site marked with a small spot of indelible ink. 
 
The first “hot spot” detected on images has to be considered as the sentinel 
lymph node. During the operation, the surgeon guided by the skin mark will locate 
the lymph node with the highest radioactivity, with the hand held gamma probe. All 
nodes with radioactive counts more than 10 times the back ground count,as 
measured in the ante cubital fossa using hand held gamma probe  are identified as 
sentinel nodes.(47). If there are two or more such lymph nodes, all should be 
removed. Before sending for histological examination, any lymph node removed 
should be re-checked by the probe to demonstrate that they are radioactive.(48) 
The disadvantages of SLNB 
1. Skip metastasis alter management predictions. 
2. Learning curve  
3. Radionuclide retention in tissues. 
4. Failure to identify sentinel nodes 
 
Pathological evaluation of SLNs 
 Pathological assessment of the SLN is done both intra operatively and post 
operatively. Intraoperative assessment permits axillary surgery in a single session if 
the SLN is positive intraoperatively or truly negative on the definite histopathologic 
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evaluation. The postoperative examination provides the final histopathologic status 
of the SLN for the definitive decision to be taken for further loco regional and 
systemic treatment. 
Intra operative evaluation 
 Intra operative examination, at the beginning of SLN era was done only to 
evaluate the nodal tissue, because the tissue removed may not represent true lymph 
node .Intra operative evaluation is used only if it influences immediate 
management. Both frozen sections and imprint have been very efficient in detecting 
metastases intra operatively (50) 
 Frozen section 
Each SLN is grossly sectioned at 0.2 cm interval portions. The most 
superficial 25% of the thickness of each resulting 0.2 cm SLN tissue section is 
processed for frozen section analysis, providing at least three separate levels of 
tissue for frozen section analysis. These frozen sections are then hand-stained by 
routine Hematoxylin and Eosin (H&E) staining. The remaining tissue of each 
resulting 0.2 cm SLN tissue section, encompassing 75% of the thickness of that 
tissue, is then sent for routine processing. (51) 
 Imprint cytology 
Excised lymph nodes submitted for intraoperative evaluation are examined 
using one of 2 methods depending on which institution is performing the 
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evaluation. In the first method, the SLN   is bisected along the long axis. Care is 
taken to obtain complete cross sections of the maximum diameter, preferably 
including the hilum and the marginal sinus. For each lymph node half, a pair of 
imprints is made by gently touching the cut surface of the SLN to a glass slide. One 
imprint from each pair is air dried and stained with the Diff-Quik stain. The second 
imprint from each surface is immediately fixed in 95% ethanol for 3 minutes and 
then stained with hematoxylin and eosin (H&E). In the second method, the SLN is 
sliced into 4-mm slices and imprints are made of each cut surface, air-dried, and 
stained with Diff-Quik(52) 
Post-operative examination 
The extent and meticulousness of the histopathologic work-up of SLNs 
should depend on the relevance of the results for further treatment decisions. The 
prognostic significance of micrometastasis, their predictive role for the involvement 
of non-SLNs, and the clinical consequences of a false-negative staging due to 
undetected micrometastasis still are being debated. However, the clinical 
implications of micrometastatic involvement of SLNs do not justify a systematic 
search for all micrometastasis. There is no doubt that all macrometastasis should be 
detected during the definitive pathologic examination. 
1embedding of the lymph node and a homogeneous distribution of the levels 
histologically examined. This can be achieved by producing SLN slices of 3 mm 
thickness for the macroscopic examination and for step sectioning. In instances of 
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negative macroscopic findings, the slices should be examined at regular, 500um 
intervals (maximum, 6 steps). This approach provides a theoretical detection rate 
for macrometastasis of 100% (53). 
 
Immune histochemistry (IHC) 
The use of cytokeratin may facilitate pathological finding. The use of 
immunohistochemistry   in the evaluation of SLNs is controversial. If the aim is to 
correctly stage the disease with the exclusion of micrometastasis then the IHC 
should be used. 
 
Molecular pathology 
 Molecular methods using  reverse transcriptase polymerase chain reaction 
have been used to detect the tumour cell. Reverse transcriptase-polymerase chain 
reaction analysis is a highly sensitive method. However, it is difficult to find a 
RNA sequence that is specific for single tumours. Hence, it may be necessary to 
use a panel of markers. High sensitivity, however, is associated with the risk of 
false-positive result 
 Results from the American College Of Surgeons Oncology 
(ACOSOG)study Z0010,confirm that IHC detected metastases  have no impact on 
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overall survival.(54) Thus routine IHC or PCR is not recommended for the 
valuation of SLNs in guidelines published by ASCO 2014,NCCN 3.2014 and 
others.(55) 
Documentation of histopathological findings 
SLNB requires standardized documentation of the histologic findings. Every 
SLN must be sent separately for histopathologic examination with a specific 
identification number. The location and sequence of removal and the method of 
detection (including target count)should be documented by the surgeon. The 
histopathologic results are reported as the pathologic lymph node (pN) category 











STAGING OF CARCINOMA  BREAST 
International Union Against Cancer (UICC) TNM classification system and 




TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
Tis(DC
 
Ductal carcinoma in situ 
Tis(LC
 
Lobular carcinoma in situ 
Tis 
(Paget) 
Paget disease of the nipple NOT associated with invasive carcinoma 
and/or carcinoma in situ (DCIS and/or LCIS) in the underlying breast 
parenchyma. Carcinomas in the breast parenchyma associated with Paget disease 
are categorized based on the size and characteristics of the parenchymal disease, 









T1 Tumour ≤ 20 mm in greatest dimension 
T1mi Tumour ≤ 1 mm in greatest dimension 
T1a Tumour> 1 mm but ≤ 5 mm in greatest dimension 
T1b Tumour> 5 mm but ≤ 10 mm in greatest dimension 
T1c Tumour> 10 mm but ≤ 20 mm in greatest dimension 
T2 Tumour> 20 mm but ≤ 50 mm in greatest dimension 
T3 Tumour> 50 mm in greatest dimension 
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T4 Tumour of any size with direct extension to the chest wall and/or to the 








T4a Extension to chest wall, not including only pectoralis muscle 
adherence/invasion 
 T4b Ulceration and/or ipsilateral satellite nodules and/or edema (including 
peaud’orange) of the skin, which do not meet the criteria for inflammatory 
carcinoma 
T4c Both T4a and T4b 
T4d Inflammatory carcinoma 




NX Regional lymph nodes cannot be assessed (eg, previously removed) 
N0 No regional lymph node metastasis 
N1 Metastasis to movable ipsilateral level I, II axillary lymph node(s) 
N2 
Metastases in ipsilateral level I, II axillary lymph nodes that are clinically 
fixed or matted or in clinically detected* ipsilateral internal mammary nodes in 
the absence of clinically evident axillary lymph node metastasis 
N2a Metastases in ipsilateral level I, II axillary lymph nodes fixed to one 
another (matted) or to other structures 
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N2b Metastases only in clinically detected* ipsilateral internal mammary 
nodes and in the absence of clinically evident level I, II axillary lymph node 
 
N3 Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s), 
            
            
            
          
    
N3a Metastasis in ipsilateral infraclavicular lymph node(s) 
N3b Metastasis in ipsilateral internal mammary lymph node(s) and axillary 




*"Clinically detected" is defined as detected by imaging studies (excluding 
lymphoscintigraphy) or by clinical examination and having characteristics highly suspicious for 
malignancy or a presumed pathologic macrometastasis on the basis of fine-needle aspiration 








Regional lymph nodes cannot be assessed (for example, previously 




No regional lymph node metastasis identified 
histologically. Note: Isolated tumour cell clusters (ITCs) are defined as small 
clusters of cells ≤ 0.2 mm, or single tumour cells, or a cluster of < 200 cells in a 
single histologic cross-section; ITCs may be detected by routine histology or by 
immunohistochemical (IHC) methods; nodes containing only ITCs are excluded 
from the total positive node count for purposes of N classification but should be 




No regional lymph node metastases histologically, negative IHC 
pN0(i+
) 
Malignant cells in regional lymph node(s) ≤ 0.2 mm (detected by 
haematoxylin-eosin [H&E] stain or IHC, including ITC) 
pN0(m
ol-) 
No regional lymph node metastases histologically, negative molecular 
findings (reverse transcriptase polymerase chain reaction [RT-PCR]) 
pN0(m
ol+) 
Positive molecular findings (RT-PCR) but no regional lymph node 
metastases detected by histology or IHC 
pN1 
Micro metastases; or metastases in 1-3 axillary lymph nodes and/or in 
internal mammary nodes, with metastases detected by sentinel lymph node 
biopsy but not clinically detected† 
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pN1mi Micro metastases (> 0.2 mm and/or > 200 cells, but none > 2.0 mm) 
pN1a Metastases in 1-3 axillary lymph nodes (at least 1 metastasis > 2.0 mm) 
pN1b 
Metastases in internal mammary nodes, with micro metastases or macro 
metastases detected by sentinel lymph node biopsy but not clinically detected† 
pN1c 
Metastases in 1-3 axillary lymph nodes and in internal mammary lymph 
nodes, with micrometastases or macrometastases detected by sentinel lymph 
node biopsy but not clinically detected† 
pN2 
Metastases in 4-9 axillary lymph nodes or in clinically detected‡ internal 
mammary lymph nodes in the absence of axillary lymph node metastases 
pN2a 
Metastases in 4-9 axillary lymph nodes (at least 1 tumour deposit > 2.0 
mm) 
pN2b 
Metastases in clinically detected‡ internal mammary lymph nodes in the 
absence of axillary lymph node metastases 
pN3 
Metastases in ≥ 10 axillary lymph nodes; or in infraclavicular (level III 
axillary) lymph nodes; or in clinically detected‡ ipsilateral internal mammary 
lymph nodes in the presence of ≥ 1 positive level I, II axillary lymph nodes; or in 
> 3 axillary lymph nodes and in internal mammary lymph nodes, with 
micrometastases or macrometastases detected by sentinel lymph node biopsy but 
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not clinically detected†; or in ipsilateral supraclavicular lymph nodes 
pN3a 
Metastases in ≥ 10 axillary lymph nodes (at least 1 tumour deposit > 2.0 
mm); or metastases to the infraclavicular (level III axillary lymph) nodes 
pN3b 
Metastases in clinically detected‡ ipsilateral internal mammary lymph 
nodes in the presence of ≥ 1 positive axillary lymph nodes; or in > 3 axillary 
lymph nodes and in internal mammary lymph nodes, with micrometastases or 
macrometastases detected by sentinel lymph node biopsy but not clinically 
detected† 
pN3c Metastases in ipsilateral supraclavicular lymph nodes 
*Classification is based on axillary lymph node dissection, with or without sentinel lymph 
            




             




            
             
             
Distant metastasis (M) 
M0 No clinical or radiographic evidence of distant metastasis 
cM0(i+
) 
No clinical or radiographic evidence of distant metastases, but deposits of 
molecularly or microscopically detected tumour cells in circulating blood, bone 
marrow, or other non regional nodal tissue that are no larger than 0.2 mm in a 
patient without symptoms or signs of metastases 
M1 Distant detectable metastases as determined by classic clinical and 






 Management of positive sentinel node. 
Isolated tumour cells 
 The seventh edition of the American Joint Committee on Cancer (AJCC) 
tumour node metastasis (TNM) staging system for breast cancer includes a   
stringent classification for lymph node findings of isolated tumour cell clusters and 
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single cells. Small clusters of cells not greater than 0.2 mm, or non-confluent or 
nearly confluent clusters of cells not exceeding 200 cells in a single histologic 
lymph node cross section, are classified as isolated tumour cells and are considered 
prognostically similar to node negative patients.  
Malignant cells in regional lymph node(s) no greater than 0.2 mm are 
designated as pN0(i+). Isolated tumour cells are not considered an indication for 
further axillary surgery, radiation treatment, or adjuvant systemic therapy. The 
finding of isolated tumour cells in lymphatics as a result of iatrogenic displacement 
from core biopsy procedures has been observed and is not considered to be 
clinically significant.(56-57) 
Micrometastases — SLND allows the pathologist to perform a more 
detailed study of few lymph nodes that most likely contain metastases this has the 
potential to improve the staging accuracy, but with increase in the rate of 
identification of micro metastatic nodal involvement(58). For this reason, there is a 
separate designation of pN1mi (>0.2 mm and no greater than 2.0 mm) to   indicate 
the micrometastasis alone. 
Although patients with micrometastasis are considered node positive, this 
finding does not change the survival compared with those without 
micrometastasis.(59).However some analyses suggest a negative impact of micro 
metastases on outcomes  including regional recurrence rate. Pathological evaluation 
for occult metastases in a randomised trial of patients who underwent SLND alone 
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or SLND plus ALND for invasive breast cancer detected occult metastases in 16% 
of patients (60). 
 In the management of positive SLN nodes, there is general acceptance of 
the following approaches.  
Patients with SLN showing isolated tumour cells are considered node 
negative and completion ALND is not indicated (61)  
 In patients with a positive SLN showing micrometastasis or 
macrometastasis in three or more nodes detected with standard hematoxylin 
& eosin  examination , completion ALND is indicated(62). The timing  of 
the procedure immediate versus delayed does not seem to affect the  total 
lymph node yield or the rate of long term complications(63) 
 Completion ALND in patients showing micrometastasis or macrometastasis in less 
than three nodes may not be necessary  because the SLN is the sole tumour-bearing 
node in up to 60 percent of cases overall, and in almost 90 percent of patients who 
harbour only micrometastatic disease. These observations have led to speculation 
that completion ALND may not be necessary in selected patients with a positive 
SLND in less than three nodes because the need for systemic therapy is established 
(64) and the risk of an axillary recurrence appears to be low(65-66). 
 A retrospective review of  studies including  randomized and prospective  
trials  with at least two years follow up supports a completion ALND in select 
group of patients with following criteria(67) 
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1. Palpable or needle proven axillary metastases 
2. SLN positive undergoing mastectomy without radiation therapy 
3. Three or more SLN positive 
Important trials  and current guidelines  in the management of SLN positive 
patients. 
1. ACOSOG Z –0010 
A multicenter prognostic study of sentinel node (SN) and bone marrow 
(BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer  
Patients underwent breast conservation surgery and SNB with bilateral iliac 
crest BM aspiration. BM and histologically negative SN were evaluated with IHC.  
This study evaluated prognostic significance of metastases detected in bone 
marrow by IHC and   metastases  detected in SLN by routine histopathology and 
IHC   
In multivariate  analysis there was no  difference in  Overall survival (OS), 
disease-free survival, and loco regional recurrence in patients tested negative for 




In a subset analysis it was seen that there was no significant difference in the 
rate of sentinel node identification with the use of blue dye alone or radio colloid 
alone or the combination of the two 
This study, questions the routine examination of SN by IHC.(68)  
2.ACOSOG Z –0011 
This study was designed to address the need for completion ALND for 
patient with less than three SLN positive. All were treated with breast conservation 
surgery and whole breast radiation therapy (69).Women with clinically T1, T2, N0 
and a positive sentinel node were randomly assigned into two arms, ALND versus 
No ALND. Primary end point   was Overall Survival (OS) and secondary end 
points were   axillary recurrence  and  surgical morbidities 
The results of the trial included, at a median follow-up of 6.3 years, no 
significant differences in survival or loco regional recurrence between the SLND 
with ALND group versus the SLND alone group. The five-year overall survival 
was similar whether women were treated with SLND plus ALND or with SLND 
alone (91.9 versus 92.5 percent, respectively) (HR 0.79, 90% CI 0.56-1.10).The 
five-year disease-free survival was also similar between the two arms (82.2 versus 
83.9 percent, respectively).Recurrence rates in the ipsilateral axilla were similar 
between the two arms with four recurrences (0.9 percent) in the SLND alone arm 
compared with two recurrences (0.5 percent) in the SLND plus ALND arm. 
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Women  in the ALND group had a significantly greater incidence of postoperative 
complications than did the SLN-only group (70% vs25%). 
The ACOSOG Z-0011 trial was criticized for a number of performance 
deficiencies; including target accrual for ACOSOG Z-0011 study was 1900 
patients. The study closed prematurely because of low accrual and low event rate 
after enrolling 436 patients in the SLND alone arm and 420 in the SLND plus 
ALND arm. The trial was not adequately powered to meet the predetermined 
statistical survival primary endpoint due to low accrual. Eleven patients assigned to 
the SLND only arm did have an ALND and 32 patients assigned to the SLND plus 
ALND arm did not have an ALND. Almost 20 percent of patients were lost to 
follow-up and 7 percent of patients in the SLND arm were found to be node 
negative compared with 1 percent of the ALND arm. There was no breakdown of 
the numbers of patients with isolated tumour cell clusters, micrometastasis or 
macrometastasis in the two arms. The majority of patients had T1 (almost 70 
percent), hormone receptor positive tumours (85 percent). Estrogen receptor status 
and adjuvant systemic therapy were independent predictors of survival. 
Based upon the apparent lack of regional benefit and low risk of events in 
this trial, completion ALND may not be necessary for all women with T1 tumours 
that are clinically node negative,  treated with breast conservation surgery ,with less 
than three positive SLNs, who will be treated with whole breast radiation, 
particularly in women with estrogen receptor positive tumours. 
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 This was also shown in a retrospective review of 242 consecutive patients 
who met the ACOSOG Z0011 criteria (70). 
 When completion ALND is omitted in patients with a positive SLND, 
whole breast radiotherapy is indicated. If partial breast radiation is planned, 
completion ALND should be performed. 
3. IBCSG 2301 trial- the international Breast Cancer Study group trial 
2301 
 This trial analysed in patients with micro metastases in SLNs  -ALND vs. 
No ALND 
 Patients with SLN micrometastasis (<2 mm) and primary tumours <5 cm in 
size were randomized to completion for ALND Vs. no additional axillary surgery 
(71). The primary end-points were five-year disease-free survival (DFS) and 
overall survival (OS) rates.  
The results of the trial  showed that with a median follow-up of 49 months, 
there was no significant difference in DFS rate for patients treated with an ALND 
compared with those treated with a SLND (87 versus 92 percent).There was no 
significant difference in OS rate for patients treated with an ALND compared with 
those treated with a SLND (97.6 versus 98.0 percent).The results of this trial, when 
considered in the context of the ACOSOG Z0011 trial, offer additional support to 
the concept that a subset of patients with metastases to sentinel nodes may in fact 
44 
 
do well with SLND alone as compared with a completion ALND. However, the data 
are derived from studies that are underpowered and have relatively short follow-up. 
3. AMAROS trial(After Mapping of the Axilla: Radiotherapy Or Surgery) 
Radiotherapy or surgery of the axilla after a positive sentinel node in breast 
cancer (EORTC 10981-22023AMAROS) (72) was  studied  
Patients were randomly assigned (1:1) by a computer-generated allocation 
schedule to receive either axillary lymph node dissection or axillary radiotherapy in 
case of a positive sentinel node, stratified by institution. The primary end point was 
non-inferiority of 5-year axillary recurrence, considered to be not more than 4% for 
the axillary radiotherapy group compared with an expected 2% in the axillary 
lymph node dissection group. 
5-year axillary recurrence was 0·43% (95% CI 0·00-0·92) after axillary 
lymph node dissection versus 1·19% (0·31-2·08) after axillary radiotherapy. The 
planned non-inferiority test was underpowered because of the low number of 
events. Lymphoedema in the ipsilateral arm was noted significantly more often 
after axillary lymph node dissection than after axillary radiotherapy at 1 year, 3 
years, and 5 years. 
Results prove Axillary lymph node dissection and axillary radiotherapy after 
a positive sentinel node provide excellent and comparable axillary control for 
patients with T1-2 primary breast cancer and no palpable lymphadenopathy. 
Axillary radiotherapy results in significantly less morbidity. 
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4. NCCN guidelines version  3.2014– recommendation 
 ALND   may be avoided in patients who have positive SLN provided all the 
following criteria are met 
1. T1 or T2 tumours 
2. 1 or 2 positive sentinel nodes  
3. No neo adjuvant chemo therapy 
4. Breast conservation therapy 
5. Whole breast Radiation Therapy is planned 
 ALND should be performed even if one of the above criteria   is not met 
 ASCO guidelines 2014(73) 
In patient with less than three SLN positive node, completion ALND need 
not be performed, provided there is no evidence of bulky metastatic disease, gross 
extra capsular extension and the patient is treated with whole breast irradiation. 
Complications of axillary lymph node dissection 
1.Seroma 
2.Arm morbidity  
3. Infection 
4. Hematoma 
          5.  Nerve injury 
1. Seroma – The normal lymphatic drainage of the breast to the axilla can 
lead to   seroma formation after axillary dissection (78, 79). Seromas can be 
diminished with the use of drains or managed via percutaneous aspiration  
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2. Arm morbidity – Lymphedema of the arm is a potential and serious 
complication of ALND. The rate varies substantially with the level of 
dissection and whether or not postoperative radiation therapy is 
used. Shoulder stiffness, and numbness and paresthesias in the upper arm are 
common complaints following an ALND. Although these symptoms do not 
usually interfere with daily living, they may reduce the quality of life (80, 
81). 
          3. Infection – The incidence of postoperative wound infection following 
axillary dissection varies from 3 to 15 percent in the literature (77).The most 
common organisms are usually gram positive (streptococcal or staphylococcal 
species) and will respond to treatment with appropriate oral antibiotics. If there is 
an underlying seroma, it should be aspirated and cultured to direct antibiotic 
treatment.  
        4.Hematoma – The reported incidence of postoperative hematoma has        
varied from 2 to 10 percent  
 
     5. Nerve injury- The risk of major motor nerve injury following an 
ALND is <1 percent. Injury to the long thoracic nerve results in a winged scapula. 
Injury to the thoracodorsal nerve weakens shoulder abduction and internal rotation. 
Injury to the medial pectoral nerve may lead to atrophy of the lateral aspect of the 
pectoralis major muscle, which may impact the overall cosmetic result. Transection 
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of the intercostobrachial nerve results in numbness and paresthesias on the inner 
upper arm.  
Complications of sentinel node biopsy 
1. Axillary paresthesia- 8.6% 
2. Seroma-7.1% 
3. Lymphedema-6.9% 
4. Decreased range of motion-3.8% 
5. Hematoma-1.4% 
     6.Axillary wound infection-1% 
     7.Axillary web syndrome. 
Axillary paraesthesia was found in 8.6% presumably due to damage to the 
inter-costobrachial nerve. Decreased range of motion was reported in 3.8% and 
lymphedema in 6.9 %.( 74) Axillary web syndrome is the development of  palpable 
tender cords in the axilla antecubital fossa or upper arm It occurs after SNB but less 
commonly than ALND. The pathogenesis proposed by research groups is 
lymphovenous damage, hyper coagulation, superficial venous and lymphatic stasis 
as well as disorders and injuries of tissues as a result of the disruption of superficial 
lymphatics and vessels during axillary surgery. The condition can be treated by 
physiotherapy and massage (75). 
 SLNB is associated with significantly less subjective and objective long-
term morbidity than ALND((82). The risk of lymphedema reported with SLN 
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biopsy is 2% to7% compared with a lifetime risk of lymphedema with ALND of 
25%.Lucci et al12 compared the postoperative complication rate of women 
undergoing SLN vs. SLN and ALND in the ACOSOG Z0011study. They found 
that women in the ALND group had a significantly greater incidence of 
postoperative complications than did the SLN-only group (70% vs. 25%). 
Complications included wound infection, axillary seromas, axillary paresthesias, 
brachial plexus injury, and lymphedema. As reported subjectively by study 
participants, the development of lymphedema was 13% at 1 year in the ALND 
group vs. 2% in the SLN-only group. 
  
Axillary recurrence after SNB 
Axillary recurrence is rare after negative sentinel node biopsy. In 2000 Giuiliano 
and colleagues published the first prospective report of patients with negative SLNs 
being treated without ALND After surgery, all decisions regarding systemic 
adjuvant treatment and radiotherapy were based on conventional criteria. . With a 
median follow up of 39 months there was no axillary recurrence (83). Naik and 
colleagues (84) studied  patients who underwent SNB  and found axillary 
recurrence rate 1.4%  the rate of recurrence was higher in patients  who had 
positive SLNs and did not undergo ALND .Axillary recurrence can be treated with 
ALND(85) . 
False negative rates of SLN biopsy 
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 The false rates of SLN biopsy has been reported to be 6.7%to 9.7% .A false 
negative rate may increase the risk of axillary recurrence .In the NSABP-32 trial, 
the site of the tumour, the type of biopsy, and the number of SLNs removed all 
affected the false negative rate. Studies have confirmed that combination of blue 
dye and radio colloid has the highest sentinel node identification rate and the lowest 
false negative rate (86). A previous excisional biopsy has the potential to increase 
the false negative rate, as the dye or radioactive material may enter the seroma 
cavity.  
Special considerations 
Sentinel node biopsy in prophylactic mastectomy 
Some surgeons perform SNB for prophylactic mastectomy because of the 
possibility of finding an occult carcinoma in the breast upon pathological 
evaluation. If invasive carcinoma is found after the surgery SNB is no longer 
possible and ALND should be performed. King  &Colleagues studied the use of 
SNB in prophylactic mastectomy. Occult carcinoma was found in 8.0 %. 
DuPont&Colleagues  also published a series of patients  with 3.5% occult  
carcinoma in prophylactic mastectomy(87). Another consideration is in the event of 
immediate reconstruction ALND may alter the cosmetic appearance or may 
compromise the vascularity of the flap. These complications can be avoided with 
SNB. 
Sentinel node biopsy in ductal carcinoma in situ (DCIS) 
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 Patients with Ductal carcinoma in situ, who undergo breast conservation 
surgery do not require axillary staging, however women with DCIS may be 
candidates for SLN biopsy if they are undergoing mastectomy. Since it would be 
essentially impossible to perform an SNB subsequently if invasive cancer is found 
in the specimen  which  would  necessitate  an ALND. Axillary surgery would be 
problematic even more if immediate reconstruction was completed with free flaps 
or flaps with Trans-axillary pedicles. For these reasons SNB is indicated for 
patients  undergoing mastectomy for DCIS. 
Sentinel node biopsy and large tumours 
Most of the initial trials with SNB were for small tumours .Chung and 
Colleagues(88)   performed SNB in tumours >5cm size .SNB accurately predicted 
the nodal status with false negative rate of 3%. Large tumours have high incidence 
of axillary metastases but with clinically node negative axilla, SNB may be 
performed  
Sentinel node biopsy after neoadjuvant chemotherapy 
Sentinel lymph node biopsy after neoadjuvant chemotherapy   in clinically 
node positive breast cancer at initial presentation    has been studied in many series. 
In NSAPB B-27(89),a neoadjuvant trial requiring ALND ,some surgeons attempted 
SNB before the required ALND. The overall success rate in sentinel node 
identification was only 84.8% after neoadjuvant chemotherapy,with false negative 
rate of 10.7%.There were no significant differences in false negative rate that were 
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associated with tumour characteristics lymphatic  mapping method  (blue dye 
,radioisotope or both) or the response to chemotherapy. The optimal timing of 
sentinel node biopsy in patients receiving neoadjuvant therapy has been debated  as 
some have reported a higher  false negative rate for SLND performed after  
induction therapy while others not(90).  
The SENTINA (SENTInelNeoAdjuvant) study (91) was designed to 
evaluate a specific algorithm for timing of a standardised sentinel-lymph-node 
biopsy procedure in patients who undergo neoadjuvant chemotherapy. SENTINA 
was a four-arm, prospective, multicentre cohort study undertaken at 103 institutions 
in Germany and Austria.Women with breast cancer who were scheduled for 
neoadjuvant chemotherapy were enrolled into the study.  There were four arms in 
the study 
 1.Patients with clinically node-negative disease (cN0) underwent sentinel-
lymph-node biopsy before neoadjuvant chemotherapy (arm A). 
2. If the sentinel node was positive (pN1), a second sentinel-lymph-node 
biopsy procedure was done after neoadjuvant chemotherapy (arm B).  
3. Women with clinically node-positive disease (cN+) received neoadjuvant 
chemotherapy. Those who converted to clinically node-negative disease after 




4. Only patients whose clinical nodal status remained positive (ycN1) 
underwent axillary dissection without sentinel-lymph-node biopsy (arm D).  
The primary endpoint was accuracy (false-negative rate) of sentinel-lymph-
node biopsy after neoadjuvant chemotherapy for patients who converted from cN1 
to ycN0 disease during neoadjuvant chemotherapy (arm C). Secondary endpoints 
included comparison of the detection rate of sentinel-lymph-node biopsy before and 
after neoadjuvant chemotherapy, and also the false-negative rate and detection rate 
of sentinel-lymph-node biopsy after removal of the sentinel lymph node. Analyses 
were done according to treatment received (per protocol). 
The false-negative rate and detection  rate of sentinel-lymph-node biopsy 
after 
 removal of the sentinel lymph node. Analyses were done according to 
treatment received (per protocol). 
Results of the study of SENTINA  trial include, sentinel-lymph-node biopsy 
is a reliable diagnostic method before neo adjuvant chemotherapy. After systemic 
treatment , the procedure has a lower detection rate and a higher false-negative rate 
compared with sentinel-lymph-node biopsy done before neo adjuvant 
chemotherapy. These limitations should be considered if biopsy is planned after 
neo adjuvant chemotherapy. 
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The 3.2014 NCCN guidelines recommend that SLND be performed prior to 
neoadjuvant chemotherapy as it provides valuable prognostic information for 
planning loco regional treatment (92) 
ACOSOG Z 1071 found a 12.6% false negative rate in when SLB performed 
post neoadjuvant chemotherapy (93). This limits the use of the procedure until 
further refinement either in the technique or patient selection. 
 In 2014 ASCO guidelines indicate that there is insufficient data at present to 
support the use of sentinel node biopsy after the neo adjuvant chemotherapy given 
the high false negative rates in the published trials (94) 
   Sentinel node biopsy in  clinically node positive axilla 
 Most of the studies in the SLN biopsy have excluded clinically suspicious 
axillary nodes. It is well known that  determination of the axillary lymph node 
status by clinical examination alone is unreliable with positive predictive 
value(PPV)  of 64%-82% and a negative predictive value (NPV ) of 50%-63% with 
overall accuracy of 63%-68%.(95)Specht&colleagues  published a review of SNB 
in patients  with clinically suspicious axillary nodes(96) and concluded  that the 
clinical axillary examination in breast cancer is subject to false-positive results, and 
is by itself insufficient justification for axillary lymph node dissection. 
 If other means of preoperative assessment such as palpation- or image-
guided fine needle aspiration are negative or indeterminate, then SLN biopsy 
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deserves wider consideration as an alternative to routine axillary lymph node 
dissection in the clinically node-positive setting. NCCN 3.2014 guidelines 
recommend FNA of the clinically suspicious axillary node and if it is negative then 
SNB can be done.  
 Sentinel node biopsy in male breast cancer 
The vast majority of published studies of SLB   for breast cancer are in 
women since the male breast cancer is uncommon. A retrospective study of 30 men 
with breast cancer reported a 100 per cent identification rate (97). Prospective 
studies are yet to be carried out. The principles that apply for SLB in female breast 
cancer appear to apply in male breast cancer.ASCO guidelines2014 acknowledges 
that there is limited data to support the use of SNB in men but there  are no 
compelling reasons it should not be successful. 
 
 
Sentinel node biopsy in pregnancy 
Pregnancy associate breast cancers tend to present at a later stage and   be 
estrogen receptor negative.  The safety of SNB in pregnancy has not been 
established.  Vital dyes such as Isosulfan blue dye should not be administered due 
to lack of safety. Methylene blue dye and 99m Technetium can be safely 
administered. A retrospective study by Gropper  et al (98) that included 25 
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clinically node negative pregnant patients who were administered methylene blue 
(n = 7) or 99-Tc (n = 16), and two with unknown injection material, found at 2.5 
years of follow-up no adverse fetal outcomes that could be attributed to the 
injection. Injections were performed at various trimesters. There were 25 livebirth 
infants, 24 of whom were deemed healthy at delivery; one infant had a cleft lip not 
attributed to the injection. 
.NCCN  3.2104 guidelines conclude   that radio colloid is safe during 
pregnancy. 




Sentinel node biopsy in multicentric and multifocal breast cancer 
Multicentric and multifocal diseases have been a relative contra indication to 
SNB in the past. Some recent studies of SNB with multifocal and multicentric 
tumours have shown effectiveness. Tousimis and colleagues (99) retrospectively 
studied patients with multicentric and multifocal tumours who underwent SNB and 
reported 96% accuracy with a false negative rate of 8%.They recommend SNB for 
multifocal and multicentric tumours that are  smaller than 5cm.  ASCO guidelines 
2014 states that SNB  may be performed for multifocal and multicentric  tumours  
and a sub areolar or intradermal injection is the preferred method 
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Sentinel node biopsy for in breast tumour recurrence 
 Patients treated with breast conservation surgery and SNB  may have 
ipsilateral in breast tumour recurrence. Taback and colleagues studied 15 patients 
with in breast tumour recurrence patients with SNB (100 )After breast conservation 
surgery radio colloid migration time was longer and the drainage was more variable 
compared with primary breast cancer.   Repeat sentinel node biopsy   is becoming 
more frequently employed and further study is indicated, including the optimal 
interval before repeat sentinel node biopsy should be attempted.(101)  Preoperative 
lymphoscintigraphy should be done if SNB is planned, as these patients often have 
alternate drainage patterns. 
 
Sentinel node biopsy in inflammatory breast cancer. 
Insufficient data exist regarding the use of SNB in inflammatory breast 
cancer. It is likely that the procedure would not be successful as the  dermal 
lymphatics  will be infiltrated with tumour emboli  SNB should not be performed in 
patients with inflammatory breast cancer it is one of the absolute contra indication 
for SNB. 
Sentinel node biopsy after previous axillary surgery 
Sentinel node biopsy may fail when the previous operation has removed 
more than 10 nodes.(102) 
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SLN  MAPPING  OF  NONAXILLARY  NODES    
SLN procedures can identify non axillary metastases in up to 43% of cases 
depending upon the primary tumour location and size, volume of the colloid 
injected and injection technique(103 ).Whether  this is useful or not is controversial 
since majority of the published data  regarding treatment and  outcomes were  from 
evaluation of axillary nodes. 
   -Internal mammary nodes 
     Internal mammary (IM) nodes are commonly found  in medial tumours 
more than 2cm size with a rate of 21%. (104).In 8-10% of the patients with axillary 
lymph nodes IM node will be found.. The diagnosis of positive IM nodes may 
affect the treatment decisions regarding adjuvant chemotherapy and regional node 
irradiation. There are limitations to the SLN technique for the identification of IM 
nodes. Interference with the radioactivity at the primary tumour site will not permit 
reliable identification of IM nodes(105) Non-invasive methods for IM nodes may 
be helpful including PET or MRI.The IM nodes are difficult to sample surgically, 
as separate incision will be required in case of breast conservation surgery and can 
be complicated by pneumothorax, pleural effusion or bleeding. 
The surgical management of positive IM nodes remain controversial There 
is no consensus on the need of IM nodal dissection with the detection of SLNs. In 
the absence of definitive data, dissection of the IM nodes with the SLB should be 




       -Intra mammary node  
         Intra mammary nodes are present in 1 to 28% of the breast cancer 
patients. By definition, intra mammary lymph nodes are surrounded by breast tissue 
and should be distinguished from low axillary lymph nodes. If the intra mammary 
nodes contain tumour they have the same prognostic significance as a positive 
axillary lymph nodes with respect to staging(106).ALND should be considered for 
women with positive intra mammary node  even if the axilla is clinically negative 













AIM OF THE STUDY: 
 
1. To study the feasibility of localization of  the sentinel node with the  
blue dye 
2. Compare the nodal  tumor positivity in relation to blue dye positivity  
3. To analyze whether blue dye technique can be used alone to avoid 














MATERIALS AND METHODS 
 
Study design:  
This prospective  study was carried out in Department of Surgical 
Oncology  with collaboration of Department of pathology , Government 
Royepettah Hospital, Chennai. Patients of  breast  cancer with clinically negative  
axilla or  Patients who had preoperative treatment (chemotherapy and /or RT) and 
became  clinically negative axillae, irrespective of initial axillary nodal status were  
included in the study, after obtaining informed consent. Thirty  five  patients with  
breast  cancers with stages T1-T3, N0, and one patient with T3 N1 M0 disease  who 
had become node negative post chemo therapy were included in the study.5 
patients  with    breast cancer clinically node negative axilla    were excluded from 
the study after they have found to have axillary nodes after ultrasound examination. 
Totally 36 patients were evaluated. 
 
1.Study period: September 2012 to January   2015 
          2.Inclusion Criteria: 
a.Patients with carcinoma breast with clinically negative axillary nodes. 
b.Patients who had preoperative treatment (chemotherapy and /or RT) and 
now have clinically negative axillae, irrespective of initial axillary nodal status.  
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c.Patients above 18 yrs age with ability to give consent. 
 
3.Exclusion criteria: 
a. Clinically palpable axillary nodes 
b.Prior upper limb lymphoedema 
c.Prior breast / axillary surgery 
d.History of blue dye allergy 
e.Patients taking serotonergic drugs like paroxetine, fluoxetine etc 
 
METHODS: 
 Clinical Evaluation:  
          Comprehensive history was taken and thorough clinical examination  
was done.  
       Symptoms were elaborated in detail. Side, T stage of the tumor and type 
of tumor was  noted. Axilla was examined for palpable lymph nodes. Only patients 
who were clinically negative for lymph nodes at the initial presentation or became   





       Ultrasound examination of the axilla was  done with real time scanner 
with probe head of 7.5 MHz frequency transducer.  
Axillary lymph nodes were reported at the time of examination as abnormal 
on the basis of size criteria and morphology (short-axis diameter > 10 mm, cortical 
thickening, and lobulation or loss of the normal hyper echoic hilum). If any  patient 
was found to have axillary lymph  nodes with the above mentioned features on ultra 
sonogram  they were excluded from the study. Thus  5 patients were excluded. 
Sentinel lymph node biopsy (SLNB): 
           In all selected patients  Modified Radical Mastectomy(MRM)  was 
done with an axilla first approach. After induction of anesthesia, peritumoral 
injection of  1% Methylene blue dye (4ml) at the 3, 6, 9, 12 o’clock positions was 
done. Sentinel lymph nodes were looked for after raising the superior flap and 
opening the clavipectoral fascia, within 15 minutes from the time of injection. The 
stained nodes were removed initially and sent for histopathological examination. 
Modified radical mastectomy was completed along with axillary lymph node 
dissection in all cases. The excised breast with the axillary tissue was sent for 






Post operative Histopathology:  
Primary tumor:  
       Post operative specimen of primary tumor was examined under 
hematoxylin and eosin stain after preparing paraffin sections . Tumor Grade, 
margin, tumor thickness, vascular invasion, Lymphatic invasion and pathological T 
stage were noted.  
Lymph nodes of axilla:   
    Number of nodes harvested at each level and nodes positive for blue dye 
were separately noted.  Lymph nodes were bisectioned  along the long axis and 
each lymph node half  was examined after  fixing  and staining.  
 
 For both blue dye and non blue dye nodes, the following features 
were analyzed separately 
number of nodes harvested and level of nodes 
number of nodes positive for tumor deposits and presenting with features  






ANALYSIS AND RESULTS 
The blue node positivity was  analyzed with the histopathological findings 
of the axillary lymph node dissection and the findings correlated with other  
features such as  
Site of primary 
Size of the primary 
Use of pre operative treatment 
Pre operative stage 
Pre operative pathological features 
 
The primary aim  of the study was to analyze the feasibility of sentinel 
lymph node  localization  in clinically Node negative  patients using blue dye. The 
secondary  aims were to identify the prevalence and level of involvement of lymph 
nodes in carcinoma breast and to correlate it with tumour stage and grade, 
comparison of accuracy of staging with SLNB to axillary dissection, to identify 
factors predicting the node positivity in breast cancers and to analyze whether blue 




Statistical analysis was done with Statistical   Package for the Social 
Sciences (SPSS) (version 17.0 software, USA). Quantitative data are described as 
mean and standard deviations. Data were also presented graphically with bar 
diagrams and pie charts. Data were explored for any outliers, typing errors and 
missing values. Comparison of groups was carried out for various categorical 
variables using Chi-square test of association and Univariate logistic regression 
analysis to find out any statistical association between categorical variables. The 
mean values of age and other quantitative variables analysed using one way 
ANOVA A p-value (two-tailed) < 0.05 was taken as significant. 
Age Distribution 
In this study 36 patients were evaluated, with mean age of 51 years, and age 
range was 26-70 years. Incidence was most common in the age group of 41-50 
{14/36(38.8%)} cases, followed by 51-60 years{13/36(36.1%)}cases. 
FIGURE-3 














Breast cancer Site Wise - Distribution 
In our series left sided lesions19/36{52.7%} were predominant over right 
sided lesions 17/36{47.3%}. The most commonly involved site was Upper Outer 
Quadrant (20/36) followed by Upper Inner Quadrant (8/36), Lower Outer Quadrant 





















T- Stage Distribution 
T Stage distribution includes  T 1- 2/36(5.56%) , T 2 – 28/36 (77.78%) ,























26-70 (mean 43 
years) 
Less 







Left 19 52.8 
Right 17 47.2 
Size 
 
T1 2 5.56 
T2 28 77.78 
T3 6 16.67 
Site 
UOQ 20 55.55 
UIQ 8 22.22 
   CENTRAL 4 11.11 




1 8 22.22 
2 19 52.8 
3 9 25 
 
Sentinel node was successfully identified in 32 cases.32/36(88.89%).Among  
the 32 cases there was skip metastases  to level II node in one patient.SLN was not 
identified in 4 cases 4/36 (11.11%). 
There was only one patient with node negative axilla post neoadjuvant 
chemotherapy. In that patient sentinel node was identified. 









Sentinel node Frequency Percentage 
 Identifified 32 88.89 
Not identified 4 11.11 
Total 36 100 
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TABLE-7 - Histopathology of the sentinel lymph node 
Histopathology of the 
sentinel lymph node 
Frequency Percentage 
Positive 16 50 
Negative 16 50 
Total 32 100 
Sentinel node histopathology  positivity VS rest of  axillary lymph node 
histo pathology positivity. 
TABLE-8- Comparison of histopathology sentinel node & Rest of axilla 
Histopathology 
of the sentinel 
lymph node 
Histo pathology of the rest of the axillary node P value 
Positive Negative  Total 
 
Positive 2 14 16 0.5442 
Negative 1 15 16 
Total 3 29 32 
SENSITIVITY  -   2/ 3 = 66.67% 
SPECIFICITY -    15/29   =  51.72% 
PPV   -  2/16   =  12.5% 




  When the histopathological status of axillary lymph nodes was compared to 
Sentinel lymph nodes histopathology it was seen that when  sentinel node HPE was 
positive(16/32) cases the  rest of the axilla was positive in 3 cases and negative in 
13 cases and when the sentinel node HPE  was  negative (16/32) cases the rest of 
the axilla was  also negative in 15 cases except one case . The sensitivity, 
specificity, positive predictive value and negative predictive values were 66.67%, 
51.5%, 12.5% and 93.75% respectively. 
In the present study we have dissected 867 axillary lymph nodes and total no 

















Factors affecting sentinel node identification 
TABLE-10 




 Sentinel node  
-      Identified 
Sentinel Node  
-Not identified 
Total     P value 
Age <5o 17 1 18 0.6
0 >50 15 3 18  
Side Right 16 3 19  
Left 16 1 17 0.7
 





Site UOQ 19 1 20  
UIO 7 1 8  
CEN
 
3 1 4  
LOQ 3 1 4 0.3
 Size T1 1 1 2  
T2 25 3 28  
T3 6 0 6 0.2
 Grade 1 8 0 8  
2 17 2 19  




Sentinel node histopathology  positive cases 
When analyzing the factors affecting the nodal positivity, we found that 
<50years of age,56.25% ,left sided 43.75% upper outer quadrant 37.5%.grade 2 
,62.5% were associated with sentinel node histopathology positivity but none of 
these factors except the Grade  were statistically significant. Lower the Grade 















<5o yrs 9 56.25 
>50 yrs 7 43.75 
Side Right 9 56.25 




UOQ 8 50 
UIO 4 25 
CENTRAL 2 12.5 
LOQ 2 12.5 
 
Size 
T1 0 0 
T2 12 75 
T3 4 25` 
 
Grade 
1 5 31.25 
2 10 62.5 
   









The status of axillary lymph node remains the most important predictor of 
survival in women with invasive breast cancer and this is used for making 
treatment decision. Various methods of predicting axillary lymph node status has 
been described including clinical assessment, radiological and operative 
procedures. Axillary lymph node dissection was earlier considered to be the gold 
standard for predicting the axillary lymph node status. Axillary  lymph node 
dissection may be associated with significant morbidity such as post-operative pain 
in arm, chronic lymphedema of involved arm, neuropathy  of arm, seroma 
formation, restricted shoulder mobility and  other complications. Sentinel Lymph 
node biopsy has emerged as an effective diagnostic tool in staging axillary disease.  
The major advantage of Sentinel lymph node biopsy is the lower complication rate 
compared with Axillary lymph node dissection 
The present study was conducted to assess the feasibility  of sentinel lymph 
node  localization using methylene  blue dye alone. 
  36 patients were included whose axilla was clinically negative for 
lymphadenopathy. 35 patients were subjected to primary surgery  and one patient 
was treated with  neoadjuvant chemotherapy and subsequently became node 
negative.  Although number of patients included  was small (N= 36) it was 
comparable to studies done by Krag et al(l08)(N=22) Borgstein et al(109)(N=33), 
Pijpiers et al(110)(N=34), Ikeda et al(111)(N=29) ,Motta C et al(112)(N=54), 




    36 patients were evaluated with a median age of 51  and the study group 
was similar to what is reported in literature.Sentinel node identification was higher 
in the age group  of <50 years. Patient age was inversely correlated with the ability 
to identify the SLN. This finding has been reported previously and may be related 
to the inability of the blue dye to be taken up by the lymphatic system  when 
injected  into the  fat-replaced postmenopausal breast Altan Özdemir et al(114) 
studied 32 patients  with a median age   0f 50.Arindam Mukherjee et al(115) 
evaluated 27 patients  with a median age of 43. 
  
  In this study both right and left  side were more or less equally affected  
with slight predominance of left sided  lesions(19/36). Upper outer quadrant was 
involved in (20/36)55.6%  of cases followed by upper inner quadrant 
(8/36)22.2%,central quadrant((4/36)11%  and lower outer quadrant.(4/36).sentinel 
node was identified readily in the upper outer quadrant tumors 95% followed by 
upper inner, central and lower outer quadrant locations with similar identification 
rate of 75% 
 Right side (72%) and upper outer quadrant(75%) were the most common 
side and site of tumor location in a study  by Altan Ozdemir-et al.2013  In the study 




  Clinical tumor status include T1 (2/36) 5.6%,T2(28/36)   77.8% and 
T3(6/36)16.7% and gradeI-I- (8/36)-22.2%,gradeII-(19/36)52.8% grade-
III(9/36)25% with highest sentinel node  identification in  T3 & Grade I lesions 
about  100%  
. In  this  study clinical  characteristics  did not affect sentinel node 
identification except Tumor Grade  and it is similar to the results observed by  
Kollias  et al(116)  who  studied clinical and histological factors associated with 
sentinel node identification    
        Either isosulphane blue or methylene blue can be used as a dye in senti-
nel lymph node biopsy. Methylene blue is cheaper, more easily obtainable, and is a 
dye with fewer complications as compared to isosulphane blue. Hypersensitivity 
reactions which may also be fatal are reported at a rate of 0.6 to 2.5 % following 
isosulphane blue injection. Skin necrosis, if injected intradermally ,fat necrosis, and 
fibrosis over the injection site  are among complications of methylene blue. 
However, in  the present  study, no such  complications related to methylene blue 
was encountered. In studies conducted in our country isosulphane blue was often 
preferred . In the literature, there are many studies showing that methylene blue can 
be used safely and with high success as an alternative to isosulphane blue . 
Simmons and colleagues  have identified the sentinel lymph node in 104 of 112 
patients by using methylene blue and reported that sentinel lymph node represented 
axillary status in 96.9% of patients. Bleesing et al.  compared isosulphane blue and 
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methylene blue, and found the accuracy rate as 88.5 % with isosulphane blue and as 
92.7% with methylene blue.  
         In  this  study  also sentinel node identification  with blue dye alone 
was 88.88%.In comparision other studies have reported  sentinel node 
identification, with methylene blue dye alone , ranging from 65-94%(Blessing et 
al.Simmons et al.Nour - Golshan (117), et al. 2006) , slightly improved rates with 
combination of both radioactive colloid and blue dye(94%100%). 
 In the present study, we dissected 867 axillary lymph nodes from 36 
patients and subjected for histopathological examination for evidence of metastasis. 
We could identify 80 blue stained sentinel lymph node during the procedure with 
average of 2.2 sentinel node This finding is in conjunction with identification rates 
of several authors like Giuliano et al10(1.8), Motomura K etal26(1.8),Cserni et 
al25(1.3)Cox et al20(1.92), Hill etal21(2.1),Ikeda et al07(1.95), Albertini et al11(2) 




















Canavese (2009)  202 97.1 6.5 
Krag (1998)  443 91.0 11.0 
Tafra (2001)  529 87.0 13.0 
SNAC [19] 1,080 94.5 5.5 
NSABP-B32  5,611 97.1 9.8 
ALMANAC  803 96.1 6.7 
ACOSOG Z010  5,283 98.7 0.3  
Sentinella/GIVOM  697 95.0 6.7 
Rama maniet 
al2014(119) 
















This study 36 88 6.25 
 
 
In this study of 36 cases, the sentinel lymph node detection rate was over 
88.8%  and the negative predictive value was 93.75%. The rate of false-negative 
result best defines the accuracy of Sentinel lymph node biopsy. In this  study, false-
negative result was  seen in  one patient. (6.25%). This is comparable with those of 
other published studies by Blessing et al.Simmons et al.Nour - Golshan (22), et al. 
2006) 
       Only one patient was post neoadjuvant chemo therapy in this  study. She  
initially had  T3 N1M0 disease and became node negative after 3 cycles of neo 
adjuvant chemotherapy with 5 flurouracil,  adriamycin and cyclophophamide(y c 
T3N0M0)  .In that patient we could identify the sentinel node and could accurately 
predict the axillary status, as  both sentinel nodes and rest of the axillary nodes 
were positive for malignancy.  
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Our results indicate that SLNB can reliably predict the axilla status such   
that when  sentinel node is negative for metastases, axillary dissection can be safely 
omitted.  
A recent survey on SLNB distributed by American Society of Breast 
Diseases Rapid Response Panel demonstrates that SLNB is considered to be the 
standard of care by 85% of the members who responded. It has been suggested that 
surgeons should demonstrate an SLN identification rate of more than or equal to 
90% and a false negative rate of less than 5% before they offer SLNB without 
completion axillary dissection.(120) However, before 
SLNB becomes the undisputed standard of care, randomized trials will have 
to show no difference in axillary recurrence and overall survival (OS) between 
SLNB alone and SLNB followed by axillary dissection in patients with negative 
sentinel node(s). Blue dye along with Tc99m mapping theoretically increases the 
accuracy of test but from various validation studies it is clear that blue dye 








 Pitfalls  of this study: 
1.Need for the flap raising to identify sentinel lymph node within 15 to 20 
minutes  because the dye transit time is  rapid  and blue staining of distal,  non-
sentinel axillary LNs is not uncommon 
2.Small  number  of patients 


















1. This study demonstrates that sentinel node  localization is possible with  
methylene  blue dye alone.  
2. Though limited by small sample size this study has shown a low false 
negative rate of 6.25%. which denotes  that SLN biopsy using methylene  blue dye 
alone  is a highly  reliable and predictable technique to stage the axilla in breast 
cancer patients. This technique may help to avoid   complete axillary lymph node 
dissection in sentinel node negative patients   thereby minimising the morbidity of 
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1 MALLIGA BEGUM 61/F 1356/13 LEFT CEN IA T1 N0 M0 3 IDC 0 0 0 22 1 1 0 0 22 0 NO
2 KARPAGAVALLI 44/F 453/13 LEFT UOQ IIA T2 N0 M0 2 IDC 2 0 0 12 2 1 0 2 18 0 NO
3 YASODHA 53/F 1140/14 LEFT UOQ IIA T2 N0 M0 3 IDC 2 0 0 13 1 1 0 2 13 0 NO
4 THULASI 58/F 683/13 LEFT UIQ IIA T2 N0 M0 2 IDC 0 0 0 14 3 2 0 0 19 0 NO
5 VALARMATHY 50/F 208/15 LEFT UOQ IIA T2 N0 M0 2 IDC 0 0 0 14 0 1 0 2 16 0 NO
6 KARPAGAM 48/F 606/13 LEFT UIQ IIA T2 N0 M0 2 IDC 2 0 0 16 3 2 0 2 19 0 NO
7 LAKSHMI 54/F 790/13 LEFT UOQ IIA T2 N0 M0 2 IDC 3 0 0 16 2 2 0 3 20 0 NO
8 AMUDHAVALLI 47/F 1241/14 lEFT UOQ IIA T2 N0 M0 1 IDC 1 0 0 18 2 2 0 1 22 0 NO
9 GNANAMANI 69/F 119/13 LEFT UIQ IIA T2 N0 M0 3 IDC 1 0 0 20 2 3 0 1 25 0 NO
10 MALLIGA 57/F 309/15 LEFT UOQ IIA T2 N0 MO 1 IDC 2 0 0 22 1 0 0 2 22 0 NO
11 SHANTHI 45/F 783/13 RIGHT UOQ IIA T2 N0 M0 2 IDC 1 0 0 11 1 1 0 1 13 0 NO
12 SUGUNA 54/F 1203/14 RIGHT UOQ IIA T2 N0 M0 2 IDC 3 0 0 11 0 0 0 3 10 1 NO
13 VANAJA 46/F 244/13 RIGHT LOQ IIA T2 N0 M0 2 IDC 1 0 0 12 4 2 0 1 18 0 NO
14 RAJESWARI 63/F 118/13 RIGHT UOQ IIA T2 N0 M0 2 IDC 2 0 0 14 4 2 0 2 20 0 NO
15 SAHAYARANI 40/F 725/13 RIGHT UOQ IIA T2 N0 M0 2 IDC 3 0 0 14 2 2 0 4 12 0 NO
16 RAJESWARI 55/F 504/13 RIGHT CEN IIA T2 N0 M0 3 IDC 3 0 0 16 2 1 0 0 19 1 NO
17 ANTHONY AACHI 60/F 1568/14 RIGHT LOQ IIA T2 N0 M0 3 IDC 0 0 0 16 0 0 0 3 13 0 NO
18 MAHMOODHA BEE 49/F 1279/13 RIGHT UOQ IIA T2 N0 M0 3 IDC 2 0 0 21 1 1 0 2 24 0 NO
19 JAGADEESWARI 30/F 177/13 LEFT UOQ IIB T3 N0 M0 3 IDC 3 0 0 14 3 4 0 3 21 0 NO
20 VICTORIA 50/F 1142/13 RIGHT UOQ IIB T3 N0 M0 3 IDC 3 0 0 18 2 2 0 3 22 0 NO
21 Nagarathinam 63/F 1240/13 LEFT UIQ IIA TI N0 MO 1 IDC 2 0 0 17 2 2 0 0 21 0 NO
22 ANSARI BEGUM 55/F 835/13 LEFT LOQ IIA T2 N0 M0 1 IDC 1 0 0 13 1 2 1 0 14 1 NO
23 GEETHA 39/F 985/13 RIGHT UIQ IIA T2 N0 M0 2 IDC 0 1 0 16 2 2 1 0 15 4 NO
24 PADMAVATHY 47/F 1327/13 RIGHT UOQ IIA T2 N0 M0 1 IDC 2 0 0 18 2 1 1 1 21 0 NO
25 SARASWATHY 60/F 674/13 LEFT UIQ IIB T3 N0 M0 2 IDC 3 0 0 14 2 2 1 2 18 0 NO
26 BANUMATHY 56/F 1194/12 RIGHT UOQ IIIA T3 NI M0 2 IDC 2 0 0 18 4 2 1 1 23 1 YES
27 VIJAYA 50/F 1153/12 LEFT UOQ IIA T2 N0 M0 3 IDC 2 0 0 14 4 2 2 0 20 0 NO
28 KUDRATH BEE 60/F 1650/14 RIGHT CEN IIA T2 N0 M0 1 IDC 3 0 0 12 2 2 2 1 14 2 NO
29 SAKUNTHALA 60/F 1709/14 RIGHT CEN IIA T2 N0 M0 1 IDC 3 0 0 12 2 1 2 1 15 0 NO
30 KASIAMMAL 70/F 643/14 RIGHT UIQ IIA T2 N0 M0 2 IDC 5 0 0 20 1 0 2 3 21 0 NO
31 KALAIARASI 48/F 1044/13 RIGHT UOQ IIA T2 N0 M0 1 IDC 4 0 0 21 3 3 2 2 24 3 NO
32 RAJESWARI 46/F 504/14 LEFT UIQ IIB T3 N0 M0 2 IDC 2 0 0 14 1 0 2 0 15 0 NO
33 SUDHA 26/F 347/13 RIGHT UOQ IIB T3 N0 M0 2 IDC 3 1 0 15 6 3 2 2 24 0 NO
34 RANI 55/F 1336/13 LEFT UOQ IIA T2 N0 M0 2 IDC 4 0 0 14 1 1 3 1 16 0 NO
35 JAYA 43/F 1226/13 LEFT LOQ IIA T2 N0 M0 2 IDC 3 0 0 14 2 2 3 0 14 0 NO




Abbreviations for Master Chart 
1. CD No  -  Cancer Department number 
2. UOQ  -  Upper Outer Quadrant 
3. UIQ  - Upper Inner Quadrant 
4. CEN  - Central 
5. LOQ  - Lower Outer Quadrant 
6. IDC  - Infiltrating Ductal Cacinoma 
7. BN  - Blue Dye Stained Nodes 
8. NBN  - Non Blue Dye Stained Nodes 
9. HPE  - Histopathological Examination 
10. NACT - Neoadjuvant Chemotherapy 
11. BN+ROA+ - HPE of Blue Node Positive & Rest of Axilla Positive 
12. BN+ROA- - HPE of Blue Node Positive & Rest of Axilla Negative 
13. BN-ROA+ - HPE of Blue Node Negative & Rest of Axilla Positive 
14. BN-ROA- - HPE of Blue Node Negative & Rest of Axilla Negative 
